ANTXAN2 Therapeutics, IncNot started yet
Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera
Polycythemia Vera (SNOMED CT: 109992005)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 75 (planned)
- Started
- Nov 2026
- Main results expected
- Apr 2029
- Fully finished
- Jun 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 2: Proportion of Participants per Treatment Group Maintaining Clinical Success defined as hematocrit control, not undergoing therapeutic phlebotomy and completing 12 weeks of treatment in Part 2
Measured over: Week 29 - Week 40
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07891533 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC